Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Patrícia O GuimarãesDaniel QuirkRemo Holanda de Mendonça FurtadoLilia N MaiaJosé F SaraivaMurillo O AntunesRoberto Kalil FilhoVagner M JuniorAlexandre M SoeiroAlexandre P TognonViviane C VeigaPriscilla A MartinsDiogo D F MoiaBruna S SampaioSilvia R L AssisRonaldo V P SoaresLuciana P A PianoKleber CastilhoRoberta G R A P MomessoFrederico MonfardiniHelio P GuimarãesDario Ponce de LeonMajori DulcineMarcia R T PinheiroLevent Mert GunayJ Jasper DeuringLuiz V RizzoTamas KonczOtavio Berwangernull nullPublished in: The New England journal of medicine (2021)
Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. (Funded by Pfizer; STOP-COVID ClinicalTrials.gov number, NCT04469114.).
Keyphrases
- coronavirus disease
- respiratory failure
- sars cov
- end stage renal disease
- rheumatoid arthritis
- extracorporeal membrane oxygenation
- newly diagnosed
- ejection fraction
- chronic kidney disease
- mechanical ventilation
- respiratory syndrome coronavirus
- ulcerative colitis
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- clinical trial
- community acquired pneumonia
- patient reported
- open label